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	 New	potential	enzyme	inhibitors,	fluorine‐substituted	thiobarbituric	acid	derivatives	(2,	3,	9,
8	and	12)	and	their	fused/isolated	heterocyclic	nitrogen	systems	(5,	6,	10	and	14)	have	been
obtained	from	heterocyclization	of	fluorinated	N,	Nʹ‐disubstituted	thiourea	(1,	7	and	11)	with
malonic	acid	followed	by	ring	closure	reactions	with	primary	nitrogen	reagents.	Structures	of
the	synthesized	products	have	been	deduced	from	their	elemental	analysis	and	spectral	data.
Anti‐HIV‐1	and	inhibition	of	cyclin‐dependent	kinase2	(CDK2)	for	cell	 tumor	division	for	the
synthesized	compounds	were	also	evaluated.	
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1.	Introduction	
	
Increased	use	of	anti‐HIV1	and	anti‐AIDS	agents	in	recent	
years	have	been	resulted	 in	 the	development	of	resistance	 to	
commercially	available	drugs	[1‐3].	Thiobarbituric	acids	have	
been	 reported	 to	 possess	 interesting	 biological	 and	
pharmacological	 activities	 [4‐7]	 including	 the	 inhibitors	 of	
hepatitis	 C	 virus	 NS5B	 polymerase	 [8],	 against	 nonalcoholic	
fatty	 liver	 disease	 [9],	 potent	 anticonvulsant	 [10],	 measured	
auto‐oxidation	 of	 brain	 homogenates	 from	 various	 animals	
[11],	determining	formaldehyde	and	acetaldehyde	in	food	[12],	
HIV‐1	 integrate	 inhibitors	 [13]	and	decreases	 liquid	peroxide	
in	human	plasma	 [14,15].	The	 introduction	of	 fluorine	atoms	
to	 bioactive	 molecules	 enhance	 and	 improve	 their	 pharma‐
cological	 properties	 [16‐18].	 Also,	 presence	 of	 hetero‐atoms	
increased	 membrane,	 permeability,	 which	 enhances	 the	
electrostatic	 force	 and	 hydrophobic	 binding	 stability	 against	
metabolic	 transformations	 [18‐22].	 As	 part	 of	 the	 interested	
research	 program	 in	 the	 fluorine	 substituted	 heterocyclic	
nitrogen	systems	as	biocidal	agents	[23‐27],	the	present	work	
tends	to	synthesize,	some	new	fluorinated‐thiobarbituric	acids	
full	 fused	 in	 view	 of	 their	 anti‐HIV	 and	 cyclin‐dependent	
kinase	2.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 determined	 with	 an	 electrothermal	 Bibly	
Stuart	 Scientific	 melting	 point	 Sample	 (UK).	 A	 Perkin	 Elmer	
Model	 RXI‐FT	 IR	 system	 55529	 was	 used	 for	 recording	 IR	
spectra	 of	 the	 prepared	 compounds.	 A	 Bruker	 advance	 DPX	
400	MHz	model	 uses	 TMS	 as	 internal	 standard	was	 used	 for	
recording	 the	 1H	 and	 13C	 NMR	 spectra	 of	 the	 compounds	 on	
deuterated	 CDCl3.	 A	 GC‐MS‐GP	 1000	 Ex	 model	 used	 for	
recording	 the	 mass	 spectra	 of	 the	 compounds.	 Electronic	
spectra	 recorded	 in	 ethanol	on	Shimadzu	UV	 and	visible	310	
IPC	 Spectrophotometer.	 Elemental	 analyses	 were	 performed	
in	microanalytical	Center	of	Cairo	University,	Egypt.	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	compounds	1a‐c	
	
Equimolar	amounts	of	4‐fluoroaniline	(0.001	mol)	and	aryl	
isothiocyanates	(0.001	mol)	were	warmed	in	THF	for	1	h	then	
cooled.	The	solid	product	was	filtered	off	and	crystallized	from	
ethanol	to	give	compound	1a‐c	as	yellow	crystals	(Scheme	1).	
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Scheme	1
	
	
1‐(4‐Fluorophenyl)‐3‐phenylthiourea	 (1a):	 Color:	 Yellow.	
Yield:	78%.	M.p.:	140‐141	°C.	FT‐IR	(KBr,	,	cm‐1):	3180	(NH),	
1385	 (cyclic	 NCSN),	 1255	 (C‐F),	 1210	 (C=S),	 864	 (Aryl‐CH),	
657	 (C‐F).	MS	 (EI,	m/z	 (%)):	 247	 (M+1,	 100).	 UV/Vis	 (EtOH,	
λmax,	nm,	(ɛ)):	238	(0.877).	Anal.	calcd.	for	C13H11FN2S:	C,	63.39;	
H,	4.50;	N,	11.37;	S,	13.02.	Found:	C,	63.11;	H,	4.44;	N,	11.20;	S,	
13.01%.		
	1‐(4‐Bromophenyl)‐3‐(4‐fluorophenyl)thiourea	(1b):	Color:	
Yellow.	 Yield:	 82%.	 M.p.:	 160‐161	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):		
3200	 (NH),	1380	 (Cyclic	NCSN),	1250	 (C‐F),	 1190	 (C=S),	 900	
(Aryl‐CH),	650	 (C‐F).	MS	(EI,	m/z	 (%)):	325.90	(100).	UV/Vis	
(EtOH,	λmax,	nm,	(ɛ)):	275	(0.95).	Anal.	calcd.	for	C13H10BrFN2S:	
C,	48.01;	H,	3.10;	N,	8.61;	S,	9.86.	Found:	C,	47.89;	H,	2.88;	N,	
8.41;	S,	9.66%.		
1‐(4‐Chlorophenyl)‐3‐(4‐fluorophenyl)thiourea	 (1c):	 Color:	
Yellow.	 Yield:	 87%.	 M.p.:	 162‐164	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):		
3210	 (NH),	1370	 (Cyclic	NCSN),	1260	 (C‐F),	 1185	 (C=S),	 850	
(Aryl‐CH),	700	(C‐Cl),	660	(C‐F).	MS	(EI,	m/z	(%)):	280.32	(M+,	
100).	UV/Vis	(EtOH,	λmax,	nm,	(ɛ)):	310	(1.20).	Anal.	calcd.	for	
C13H10ClFN2S:	 C,	 55.62;	 H,	 3.59;	 N,	 9.98;	 S,	 11.42.	 Found:	 C,	
54.43;	H,	3.22;	N,	9.40;	S,	10.91%.		
	
2.2.2.	Synthesis	of	compounds	2a‐c	
	
A	mixture	of	compound	1a‐c	(0.001	mol)	and	malonic	acid	
(0.001	mol)	in	a	few	drops	of	acetyl	chloride	and	glacial	acetic	
acid	 (20	mL)	was	 refluxed	 for	 2h	 then	 poured	 onto	 ice.	 The	
solid	product	was	 filtered	off	 and	crystallized	 from	dioxan	 to	
give	compounds	2a‐c	as	yellow	crystals	(Scheme	1).	
1‐(4‐Fluorophenyl)‐3‐phenyl‐2‐thioxodihydropyrimidine‐4,6	
(1H,5H)‐dione	 (2a):	Color:	Yellow.	Yield:	75%.	M.p.:	 86‐88	 °C.	
FT‐IR	(KBr,	,	 cm‐1):	3476	(OH),	2856	(Str.	CH2),	1680	(C=O),	
1497	 (Deform.	 CH2),	 1387	 (Cyclic	 NCSN),	 1255	 (C‐F),	 1180	
(C=S),	 864	 (Aryl	CH),	659	 (C‐F).	 1H	NMR	 (400	MHz,	CDCl3,	 δ,	
ppm):	2.59‐2.58	(s,	2H,	CH2),	7.96‐7.01	(m,	9H,	Ar‐H),	9.81	(s,	
1H,	OH).	 13C	NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 166.32,	 159.75,	
158.17,	 135.15,	 135.10,	 135.08,	 128.29,	 127.69,	 122.37,	
115.20,	115.05,	77.81,	40.43.	MS	(EI,	m/z	(%)):	314	(M+,	100).	
UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	 258	 (0.984).	 Anal.	 calcd.	 for	
C16H11FN2O2S:	 C,	 61.14;	 H,	 3.53;	 N,	 8.91;	 S,	 10.20.	 Found:	 C,	
61.10;	H,	3.35;	N,	8.69;	S,	10.00%.		
1‐(4‐Bromophenyl)‐3‐(4‐fluorophenyl)‐2‐thioxodihydropyri	
midine‐4,6(1H,5H)‐dione	(2b):	Color:	Yellow.	Yield:	78%.	M.p.:	
120‐122	°C.	FT‐IR	(KBr,	,	cm‐1):	 	3500	(OH),	2852	(Str.	CH2),	
1700	 (C=O),	 1488	 (Deform.	 CH2),	 1380	 (Cyclic	 NCSN),	 1188	
(C=S),	800	(Aryl	CH),	710	(C‐Br),	680	(C‐F).	MS	(EI,	m/z	(%)):	
394.1	(M+1,	95).	UV/Vis	(EtOH,	λmax,	nm,	(ɛ)):	345	(1.88).	Anal.	
calcd.	 for	 C16H10BrFN2O2S:	 C,	 48.87;	 H,	 2.56;	 N,	 7.12;	 S,	 8.14.	
Found:	C,	48.58;	H,	2.41;	N,	7.01;	S,	8.00%.		
1‐(4‐Chlorophenyl)‐3‐(4‐fluorophenyl)‐2‐thioxodihydropyri	
midine‐4,6(1H,5H)‐dione	 (2c):	Color:	Yellow.	Yield:	81%.	M.p.:	
116‐118	°C.	FT‐IR	(KBr,	,	cm‐1):	 	3410	(OH),	2848	(Str.	CH2),	
1675	 (C=O),	 1445	 (Deform.	 CH2),	 1370	 (Cyclic	 NCSN),	 1188	
(C=S),	870	(Aryl	CH),	700	(C‐Br),	676	(C‐F).	UV/Vis	(EtOH,	λmax,	
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nm,	(ɛ)):	375	(0.98).	MS	(EI,	m/z	(%)):	348	(100).	Anal.	calcd.	
for	C16H10ClFN2O2S:	C,	55.10;	H,	2.89;	N,	8.03;	S,	9.19.	Found:	C,	
54.83;	H,	2.66;	N,	7.89;	S,	8.77%.		
	
2.2.3.	Synthesis	of	compound	3	
	
A	 mixture	 of	 compound	 2a	 (0.001	 mol)	 and	 cyclohexyl	
isocyanate	 (0.001	mol)	 in	 ethanol	 (20	mL)	with	 a	 piperidine	
(0.5	mL)	was	 refluxed	 for	 8	h,	 cooled,	 and	 concentrated.	The	
solid	product	was	crystallized	from	dioxan	to	give	compound	3	
as	white	crystals	(Scheme	1).	
1‐(4`‐Fluorophenyl)‐3‐(phenyl)‐5‐(cyclohexylcarbamido)‐2,	
3‐dihydro‐2‐thioxo‐4,6‐(1H,5H)	 pyrimidine‐dione	 (3):	 Color:	
White.	 Yield:	 75%.	M.p.:	 98‐99	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	 3492	
(OH),	 3180	 (NH),	 1668	 (C=O),	 1502	 (Deform.	 CH2),	 1386	
(Cyclic	NCSN),	1255	(C‐F),	1180	(C=S),	864	(Aryl	CH),	659	(C‐
F).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	 2.14‐2.02	 (s,	 11H,	
CH2+CH),	 7.95‐7.00	 (m,	 5H,	 C6H5),	 8.02‐8.11	 (m,	 4H,	 Ar‐H),	
8.95	 (s,	 1H,	NH),	10.5	 (s,	1H,	OH).	MS	 (EI,	m/z	(%)):	439(M+,	
49).	 UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	 275.	 Anal.	 calcd.	 for	
C23H22FN3O3S:	 C,	 62.85;	 H,	 5.05;	 N,	 9.56;	 S,	 7.30.	 Found:	 C,	
62.51;	H,	4.88;	N,	9.39;	S,	7.01%.		
	
2.2.4.	Synthesis	of	compound	4	
	
Compound	3	(0.050	mol)	in	glacial	acetic	acid	(10	mL)	and	
anhydrous	sodium	acetate	(0.50	g)	was	refluxed	for	2	h	cooled	
and	poured	 onto	 ice.	 The	 solid	product	was	 filtered	 off,	 then	
crystallized	 from	 ethanol	 to	 give	 compound	 4	 as	 yellowish	
brown	crystals	(Scheme	1).		
8‐Cyclohexyl‐2‐(4‐fluorophenyl)‐4‐phenyl‐3‐thioxo‐2,4,8‐tri	
azabicyclo[4.2.0]oct‐1(6)‐ene‐5,7‐dione	 (4):	 Color:	 Yellowish	
brown.	 Yield:	 80%.	 M.p.:	 110‐112	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	
1710,	 1680	 (C=O),	 1500	 (Deform.	 CH2),	 1382	 (Cyclic	 NCSN),	
1255	(C‐F),	1181	(C=S),	864	(Aryl	CH),	657	(C‐F).	1H	NMR	(400	
MHz,	CD3Cl,	δ,	ppm):	2.22‐2.01	(s,	11H,	CH2+CH),	7.70‐7.10	(m,	
5H,	Ar‐H),	8.12‐8.02	(m,	4H,	Ar‐H).	MS	(EI,	m/z	(%)):	422	(M+,	
25.13).	UV/Vis	(EtOH,	λmax,	nm,	(ɛ)):	278	(0.88).	Anal.	calcd.	for	
C23H20FN3O2S:	 C,	 65.54;	 H,	 4.78;	 N,	 9.97;	 S,	 7.61.	 Found:	 C,	
65.28;	H,	4.55;	N,	9.77;	S,	7.42%.		
	
2.2.5.	Synthesis	of	compounds	5	and	6	
	
A	 mixture	 of	 compound	 3	 (0.001	 mol)	 and	 N‐
methyl/phenyl	 thioureas	 (0.001	 mol)	 in	 ethanolic	 sodium	
hydoxide	 (25	 mL,	 5%)	 was	 refluxed	 for	 2	 h,	 cooled	 then	
poured	into	ice‐HCl.	The	solid	product	was	filtered	off,	washed	
with	 cold	 water	 and	 crystallized	 from	 ethanol	 to	 give	
compound	5	and	6,	respectively	(Scheme	1).		
5‐(Cyclohexylamino)‐1‐(4‐fluorophenyl)‐6‐methyl‐3‐phenyl‐
2,7‐dithioxo‐2,3,6,7‐tetrahydropyrimido[4,5‐d]pyrimidin‐4(1H)‐
one	 (5):	 Color:	 Yellow.	 Yield:	 66%.	 M.p.:	 218‐220	 °C.	 FT‐IR	
(KBr,	,	 cm‐1):	 	3119	 (NH),	1659	 (C=O),	1500,	1441	 (Deform.	
CH2),	 1384	 (Cyclic	NCSN),	 1253	 (C‐F),	 1184	 (C=S),	 863	 (Aryl	
CH),	 657	 (C‐F).	 MS	 (EI,	m/z	 (%)):	 492.90	 (M+,	 46).	 UV/Vis	
(EtOH,	λmax,	nm,	(ɛ)):	315	(1.28).	Anal.	calcd.	for	C25H24FN5OS2:	
C,	60.83;	H,	4.90;	N,	14.19;	S,	12.99.	Found:	C,	60.59;	H,	4.60;	N,	
14.01;	S,	12.39%.		
	5‐(Cyclohexylamino)‐1‐(4‐fluorophenyl)‐3,	 6‐diphenyl‐2,	 7‐
dithioxo‐2,3,6,7‐tetrahydropyrimido[4,5‐d]	pyrimidin‐4(1H)‐one	
(6):	Color:	Yellow.	Yield:	75%.	M.p.:	130‐132	°C.	FT‐IR	(KBr,	,	
cm‐1):	3123	(NH),	1661	(C=O),	1499,	1438	(Deform.	CH2),	1386	
(Cyclic	NCSN),	1255	(C‐F),	1185	(C=S),	864	(Aryl	CH),	658	(C‐
F).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	2.59‐2.60	(m,	10H,	5CH2	
of	cyclohexane),	2.95‐2.96	(s,	1H,	CH),	7.96‐7.49	(m,	14H,	Ar‐
H),	 11.55	 (s,	 1H,	 NH).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	
207.02	(C=S),	157.10	(C=O),	130.01‐126.01	(Ar‐C).	MS	(EI,	m/z	
(%)):	 554.85	 (79).	 UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	 287	 (1.12).	
Anal.	 calcd.	 for	 C30H26FN5OS2:	 C,	 64.84;	 H,	 4.72;	 N,	 12.60;	 S,	
11.54.	Found:	C,	64.26;	H,	4.51;	N,	12.33;	S,	11.31%.		
	
2.2.6.	Synthesis	of	compounds	7a‐c	
	
A	mixture	of	benzoyl	isothiocyanate	(0.001	mol)	and	sulfa‐
drugs,	 namely	 sulfathiazole,	 sulfamerazine	 or	 sulfadiazine	
(0.001	mol)	in	THF	(20	mL)	was	refluxed	for	1	h,	cooled.	The	
solid	product	was	filtered	off	and	crystallized	from	THF	to	give	
compounds	7a‐c	as	yellow	crystals	(Scheme	2).	
N‐((4‐(N‐(Thiazol‐2‐yl)	 sulfamoyl)	 phenyl)	 carbamothioyl)	
benzamide	 (7a):	 Color:	 Yellow.	 Yield:	 89%.	M.p.:	 218‐219	 °C.	
FT‐IR	 (KBr,	 ,	 cm‐1):	 3300‐3100	 (NH‐NH),	 3005	 (Aryl	 CH),	
1580	(NHCO),	1499,	1386	(	NCSN),	1218	(C=S),	865	(Aryl	CH).	
1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	4.23	(s,	1H,	NH),	7.99‐7.88,	
7.65‐6.00	(each	m,	11H,	Ar‐H),	10.70	(s,	1H,	NH),	13.07	(s,	1H,	
NH).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 179.16,	 169.24,	
168.37,	 140.92,	 139.82,	 131.70,	 128.73,	 128.11,	 126.91,	
123.68,	 123.59,	 107.51,	 77.80,	 67.76,	 40.44‐39.49,	 25.44.	 MS	
(EI,	m/z	(%)):	418.31	(100).	UV/Vis	(EtOH,	λmax,	nm,	(ɛ)):	238.	
Anal.	 calcd.	 for	 C17H14N4O3S3:	 C,	 48.79;	 H,	 3.37;	 N,	 13.39;	 S,	
22.98.	Found:	C,	48.59;	H,	3.21;	N,	13.25;	S,	22.59%.		
N‐((4‐(N‐(4‐Methylpyrimidin‐2‐yl)	sulfamoyl)	phenyl)	carba	
mothioyl)benzamide	(7b):	Color:	Yellow.	Yield:	86%.	M.p.:	196‐
197	°C.	FT‐IR	(KBr,	,	 cm‐1):	 	3300‐3100	(NH‐NH),	2910	(Str.	
CH3),	 1610	 (C=N),	 1590	 (NHCO),	 1480	 (Deform.	 CH3),	 1380	
(Acyclic.	 NCSN),	 1350	 (SO2NH),	 1188	 (C=S),	 850,	 810	 (Aryl	
CH).	 MS	 (EI,	 m/z	 (%)):	 427	 (100).	 UV/Vis	 (EtOH,	 λmax,	 nm,	
(ɛ)):	266	(1.11).	Anal.	calcd.	for	C19H17N5O3S2:	C,	53.38;	H,	4.01;	
N,	16.38;	S,	15.00.	Found:	C,	53.20;	H,	3.69;	N,	16.11;	S,	14.68%.		
N‐((4‐(N‐(Pyrimidin‐2‐yl)sulfamoyl)	phenyl)	carbamothioyl)	
benzamide	 (7c):	 Color:	 Yellow.	 Yield:	 82%.	M.p.:	 150‐151	 °C.	
FT‐IR	(KBr,	,	 cm‐1):	 	3280‐3090	(NH‐NH),	1625	(C=N),	1600	
(NHCO),	1388	(Acyclic.	NCSN),	1340	(SO2NH),	1190	(C=S),	880,	
815	(Aryl	CH).	MS	(EI,	m/z	(%)):	412.56	(100).	UV/Vis	(EtOH,	
λmax,	 nm,	 (ɛ)):	269	 (0.66).	 Anal.	 calcd.	 for	 C18H15N5O3S2:	 C,	
52.29;	H,	3.66;	N,	16.94;	S,	15.51.	Found:	C,	52.09;	H,	3.55;	N,	
16.48;	S,	15.32%.		
	
2.2.7.	Synthesis	of	compounds	8a‐c	
	
A	mixture	 of	 compounds	 7a‐c	 (0.001	mol),	 malonic	 acid	
(0.001	mol)	 in	 acetyl	 chloride	 (drops)	 and	 glacial	 acetic	 acid	
(20	mL)	was	 refluxed	 for	 2	 h,	 cooled	 and	 concentrated.	 The	
solid	 product	 was	 crystallized	 from	 1,4‐dioxan	 to	 give	
compounds	8a‐c	as	yellow	crystals	(Scheme	2).		
4‐(3‐Benzoyl‐4,6‐dioxo‐2‐thioxotetrahydropyrimidin‐1(2H)‐
yl)‐N‐(thiazol‐2‐yl)benzenesulfonamide	 (8a):	 Color:	 Yellow.	
Yield:	71%.	M.p.:	190‐191	°C.	FT‐IR	(KBr,	,	cm‐1):	3540	(OH),	
3100	 (NH),	 1661	 (C=O),	 1502	 (Deform.	 CH2),	 1438	 (Deform.	
CH2),	 1385	 (NCSN),	1147	 (C=S),	 929	 (aryl	CH).	 1H	NMR	 (400	
MHz,	 CDCl3,	 δ,	 ppm):	 2.60‐2.21	 (m,	 2H,	 CH2),	 6.93‐7.52,	 (m,	
11H,	aromatic),	11.28	(s,	1H,	OH),	12.84	(s,	1H,	NH).	13C	NMR	
(100	 MHz,	 CDCl3,	 δ,	 ppm):	 179.26,	 173.06,	 169.22,	 140.96,	
139.52,	 126.84,	 123.67,	 123.44,	 107.50,	 123.68,	 77.75‐77.36,	
40.42‐39.47,	 24.08.	 MS	 (EI,	 m/z	 (%)):	 485.94	 (23).	 UV/Vis	
(EtOH,	λmax,	nm,	(ɛ)):	280	(0.246).	Anal.	calcd.	for	C20H14N4O5S3:	
C,	49.37;	H,	2.90;	N,	11.52;	S,	19.77.	Found:	C,	49.21;	H,	2.77;	N,	
11.28;	S,	19.58%.		
4‐(3‐Benzoyl‐4,6‐dioxo‐2‐thioxotetrahydropyrimidin‐1(2H)‐
yl)‐N‐(4‐methylpyrimidin‐2‐yl)benzenesulfon	amide	(8b):	Color:	
Yellow.	 Yield:	 76%.	 M.p.:	 250‐251	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	
3545	 (OH),	 3100	 (NH),	 2912	 (Str.	 CH3),1667	 (C=O),	 1500	
(Deform.	 CH2),	 1384	 (NCSN),	 1357	 (SO2NH)	 1144	 (C=S),	 923	
(aryl	CH).	MS	(EI,	m/z	(%)):	494.51	 (47).	UV/Vis	 (EtOH,	λmax,	
nm,	(ɛ)):	305	(0.95).	Anal.	calcd.	for	C22H17N5O5S2:	C,	53.32;	H,	
3.46;	N,	14.13;	 S,	12.94.	Found:	C,	53.21;	H,	3.21;	N,	14.00;	S,	
12.80%.		
4‐(3‐Benzoyl‐4,6‐dioxo‐2‐thioxotetrahydropyrimidin‐1(2H)‐
yl)‐N‐(pyrimidin‐2‐yl)benzenesulfonamide	 (8c):	 Color:	 Yellow.	
Yield:	72%.	M.p.:	224‐226	°C.	FT‐IR	(KBr,	,	cm‐1):		3547	(OH),	
3104	 (NH),	 1667	 (C=O),	 1507	 (Deform.	 CH2),	 1386	 (NCSN),	
1355	(SO2NH),	1147	(C=S),	920	(Aryl	CH).		
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MS	 (EI,	m/z	 (%)):	 480.25	 (46).	 UV/Vis	 (EtOH,	 λmax,	 nm,	
(ɛ)):	315	(1.15).	Anal.	calcd.	for	C21H15N5O5S2	:	C,	52.38;	H,	3.14;	
N,	14.54;	S,	13.32.	Found:	C,	52.15;	H,	3.01;	N,	14.31;	S,	13.09%.		
	
2.2.8.	Synthesis	of	compounds	9a	and	b	
	
To	compound	8a	 and	8b	 (0.001	mol)	 in	DMF	 (20	mL)	4‐
fluorobenzoyl	chloride	(0.001	mol)	was	added	and	warmed	for	
1h,	 cooled	 and	 poured	 onto	 ice.	 The	 solid	 product	 was	
crystallized	 from	1,4‐dioxan	to	give	compounds	9a	and	9b	as	
yellow	crystals	(Scheme	2).		
	4‐(3‐Benzoyl‐5‐(4‐fluorobenzoyl)‐	 4,6‐dioxo‐2‐thioxotetra	
hydropyrimidin‐1(2H)‐yl)‐N‐(thiazol‐2‐yl)benzene	 sulfonamide	
(9a):	Color:	Yellow.	Yield:	66%.	M.p.:	172‐173	°C.	FT‐IR	(KBr,	
,	cm‐1):	3528	(OH),	1680,	1660	(C=O),	1385	(NCSN),	1255	(C‐
F),	 1180	 (C=S),	 864	 (Aryl	CH),	658	 (C‐F).	 1H	NMR	 (400	MHz,	
CD3Cl,	δ,	ppm):	7.39‐8.05	(m,	15H,	Ar‐H),	8.51	(s,	1H,	OH),	9.80	
(s,	1H,	NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	167.52,	166.37,	
164.69,	 132.29,	 132.23,	 127.21,	 127.19,	 77.50‐77.08,	 40.44‐
39.54.	MS	(EI,	m/z	(%)):	607.89	(100).	UV/Vis	(EtOH,	λmax,	nm,	
(ɛ)):	244	(0.1035).	Anal.	calcd.	for	C27H17FN4O6S3:	C,	53.28;	H,	
2.82;	F,	3.12;	N,	9.21;	S,	15.80.	Found:	C,	53.01;	H,	2.66;	N,	9.11;	
S,	15.58%.		
4‐(3‐Benzoyl‐5‐(4‐fluorobenzoyl)‐	 4,	 6‐dioxo‐2‐thioxotetra	
hydropyrimidin‐1	 (2H)‐yl)‐N‐(4‐methylpyrimidin‐2‐yl)	 benzene	
sulfon	amide	(9b):	Color:	Yellow.	Yield:	68%.	M.p.:	159‐160	°C.	
FT‐IR	 (KBr,	 ,	 cm‐1):	 3480	 (OH),	 1700,	 1670	 (C=O),	 1590	
(C=N),	 1360	 (NCSN),	 1330	 (SO2NH),	 1250	 (C‐F),	 1188	 (C=S),	
850,820	(Aryl	CH),	660	(C‐F).	MS	(EI,	m/z	(%)):	616.85	(0.43).	
UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	265	 (0.110).	 Anal.	 calcd.	 for	
C29H20FN5O6S2:	C,	56.39;	H,	3.26;	N,	11.34;	S,	10.38.	Found:	C,	
56.27;	H,	3.08;	N,	11.32;	S,	10.21%.		
	
2.2.9.	Synthesis	of	compounds	10a	and	b	
	
A	 mixture	 of	 compounds	 9a	 and	 9b	 (0.001	 mol)	 and	 4‐
chlorophenyl	 hydrazine.HCl	 (0.001	 mol	 in	 5	 mL	 H2O)	 in	
absolute	ethanol	(20	mL)	and	sodium	acetate	(0.001	mol)	was	
refluxed	for	4	h,	cooled	and	poured	onto	ice.		
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The	 solid	 product	 was	 filtered	 off	 and	 crystallized	 from	
ethanol	to	give	compounds	10a	and	or	10b	as	yellow	crystals	
(Scheme	2).		
	4‐(7‐Benzoyl‐2‐(4‐chlorophenyl)‐3‐(4‐fluorophenyl)‐4‐oxo‐
6‐thioxo‐6,7‐dihydro‐2H‐pyrazolo[3,4‐d]pyrimidin‐5(4H)‐yl)‐N‐
(thiazol‐2‐yl)benzenesulfonamide	 (10a):	 Color:	 Yellow.	 Yield:	
55%.	M.p.:	131‐132	°C.	FT‐IR	(KBr,	,	cm‐1):	3120	(NH),	1662	
(C=O),	 1580	 (C=N),	 1385	 (NCSN),	 1340	 (SO2NH),	 1255	 (C‐F),	
1180	(C=S),	865	(Aryl	CH),	710	(C‐Cl),	657	(C‐F).	1H	NMR	(400	
MHz,	 CDCl3,	 δ,	 ppm):	 4.30	 (s,	 1H,	 NH),	 7.11‐6.72	 (d,	 2H,	
Thiazol),	7.16‐7.15	(m,	5H,	phenyl),	7.29‐7.27	(d,	4H,	4‐chloro	
phenyl),	 7.53‐7.47	 (d,	 4H,	 Ar‐H),	 8.20‐7.51	 (d,	 4H,	 4‐fluoro	
phenyl).	 13C	 NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 176.72,	 170.30,	
147.50,	146.90,	128.94,	128.68,	124.29,	114.39,	113.49,	77.82,	
40.41.	MS	(EI,	m/z	(%)):	714.01	(92).	UV/Vis	(EtOH,	λmax,	nm,	
(ɛ)):	315	(0.1118).	Anal.	calcd.	for	C33H20ClFN6O4S3:	C,	55.42;	H,	
2.82;	N,	11.75;	S,	 13.45.	Found:	C,	55.23;	H,	2.55;	N,	11.56;	S,	
13.20%.		
	4‐(7‐Benzoyl‐2‐(4‐chlorophenyl)‐3‐(4‐fluorophenyl)‐4‐oxo‐
6‐thioxo‐6,7‐dihydro‐2H‐pyrazolo[3,4‐d]pyrimidin‐5(4H)‐yl)‐N‐
(4‐methylpyrimidin‐2‐yl)benzenesulfonamide	 (10b):	 Color:	
Yellow.	 Yield:	 65%.	 M.p.:	 138‐140	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	
3160	 (NH),	 2880	 (Str.	 CH3),	 1690,	 1660	 (C=O),	 1520	 (C=N),	
1480	 (Defom.	CH3),	1365	 (NCSN),	1320	 (SO2NH),	1255	 (C‐F),	
1190	(C=S),	880	(Aryl	CH),	710	(C‐Cl),	680	(C‐F).	MS	(EI,	m/z	
(%)):	 722.76	 (59).	 UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	308	 (1.11).	
Anal.	calcd.	for	C35H23ClFN7O4S2:	C,	58.05;	H,	3.20;	N,	13.54;	S,	
8.86.	Found:	C,	57.85;	H,	2.99;	N,	13.31;	S,	8.55%.		
	
2.2.10.	Synthesis	of	compounds	11	
	
A	 mixture	 of	 4‐fluoroaniline	 (0.001	 mol)	 and	 benzoyl	
isothiocyanate	(0.001	mol)	in	THF	(20	mL)	was	refluxed	for	1	
h,	 cooled.	 The	 solid	 product	was	 filtered	 off	 and	 crystallized	
from	dioxan	to	give	compound	11	as	greenish	yellow	crystals	
(Scheme	3).		
	N‐((4‐Fluorophenyl)carbamothioyl)benzamide	 (11):	Color:	
Greenish	yellow.	Yield:	88%.	M.p.:	94‐96	°C.	FT‐IR	(KBr,	,	cm‐
1):	3230,	3150	(NH,	NH),	1680,	1660	(C=O),	1504	(C=N),	1385	
(NCSN),	 1152	 (C=S),	 864,	 808,	 719	 (Aryl	 CH),	 657	 (C‐F).	 1H	
NMR	(400	MHz,	CDCl3,	δ,	ppm):	4.23	(s,	1H,	NH),	7.00‐8.01	(m,	
9H,	Ar‐H),	8.70	(s,	1H,	NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	
176.79,	 168.19,	 161.44,	 159.86,	 133.86,	 131.81,	 128.77,	
128.73,	 128.69,	 128.21,	 126.57,	 126.52,	 126.48,	 126.43,	
115.61,	 115.46,	 77.83‐77.41,	 40.41‐39.46.	 MS	 (EI,	m/z	 (%)):	
274.03	(100).	UV/Vis	(EtOH,	λmax,	nm,	(ɛ)):	265	(1.700).	Anal.	
calcd.	 for	 C14H11FN2OS:	 C,	 61.30;	 H,	 4.04;	 N,	 10.21;	 S,	 11.69.	
Found:	C,	61.01;	H,	4.00;	N,	9.82;	S,	11.44%.		
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	2.2.11.	Synthesis	of	compounds	12	
	
A	mixture	of	compound	11	 (0.001	mol)	and	malonic	acid	
(0.001	mol)	in	a	few	drops	of	acetyl	chloride	and	glacial	acetic	
(20	ml)	was	refluxed	for	2	h,	cooled	and	poured	onto	ice.	The	
solid	product	was	filtered	off	and	crystallized	from	1,4‐dioxan	
to	give	compound	12	as	yellowish	crystals	(Scheme	3).	
1‐Benzoyl‐3‐(4‐fluorophenyl)‐2‐thioxodihydropyrimidine‐4,	
6(1H,5H)‐dione	 (12):	 Color:	 Yellowish.	 Yield:	 80%.	M.p.:	 170‐
171	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	 3539	 (OH),	 1680,	 1660	 (C=O),	
1506	(Deform.	CH2),	1438	(Deform.	CH2),	1385	(NCSN),	1255	
(C‐F),	1211	(C=S),	864,	840,	772,	710	(Aryl	CH),	658	(C‐F).	MS	
(EI,	m/z	 (%)):	341.59	 (48).	UV/Vis	 (EtOH,	λmax,	nm,	 (ɛ)):	288	
(1.029).	 Anal.	 calcd.	 for	 C17H11FN2O3S:	 C,	 59.64;	 H,	 3.24;	 N,	
8.18;	S,	9.35.	Found:	C,	59.41;	H,	3.10;	N,	8.00;	S,	9.13%.		
	
2.2.12.	Synthesis	of	compounds	13	
	
A	 mixture	 of	 compound	 12	 (0.001	 mol)	 and	 methyl	 2‐
chloromalonate	(0.001	mol)	in	dry	toluene	(20	mL)	with	a	few	
drops	of	triethylamine	(TEA)		was	refluxed	for	1h,	cooled	and	
addition	 the	 pet‐ether	 80‐100	 °C.	 The	 solid	 product	 was	
filtered	off	and	crystallized	from	1,4‐dioxan	to	give	compound	
13	as	yellowish	crystals	(Scheme	3).	
Dimethyl	 2‐(1‐benzoyl‐3‐(4‐fluorophenyl)‐4,	 6‐dioxo‐2‐
thioxohexahydropyrimidin‐5‐yl)malonate	 (13):	 Color:	 Yellow.	
Yield:	65%.	M.p.:	144‐146	°C.	FT‐IR	(KBr,	,	cm‐1):	3550	(OH),	
3080	 (aryl	CH),	 2950,	2880	 (aliphatic	CH),	1700,	1680,	1660	
(C=O),	 1506,	 1438	 (deform.	 CH2),	 1385	 (NCSN),	 1255	 (C‐F),	
1211	(C=S),	1090	(C‐O‐R),	864,	840,	772,	(aryl	CH),	658	(C‐F).	
1H	 NMR	 (400	MHz,	 CD3Cl,	 δ,	 ppm):	 1.39‐1.37	 (m,	 6H,	 2CH3),	
2.59‐2.58	 (m,	 2H,	 CH	 of	 malonate	 and	 thiobarbituric	 acid),	
7.01‐7.97	(m,	9H,	Ar‐H),	9.80	(s,	1H,	OH).	13C	NMR	(100	MHz,	
CDCl3,	δ,	ppm):	166.32,	159.79,	158.18,	135.15,	135.07,	131.45,	
128.30,	 127.69,	 122.40,	 122.35	 115.20,	 115.05.	 77.74‐77.36,	
45.87,	 40.44‐39.49.	 MS	 (EI,	 m/z	 (%)):	 472	 (100).	 UV/Vis	
(EtOH,	 λmax,	 nm,	 (ɛ)):	268	 (1.311).	 Anal.	 calcd.	 for	
C22H17FN2O7S:	 C,	 55.93;	H,	 3.63;	N,	 5.93;	 S,	 6.79	%.	 Found:	 C,	
55.79;	H,	3.50;	N,	5.77;	S,	6.45%.		
	
2.2.13.	Synthesis	of	compounds	14	
	
Equimolar	 amounts	 (0.01	mol)	 of	 compounds	11	 and	13	
was	refluxed	in	dry	1,4‐dioxan	(50	mL)	for	4h	and	cooled.	The	
solid	product	was	filtered	off	and	crystallized	from	1,4‐dioxan	
to	give	a	white	crystal	(Scheme	3).	
1,1'‐Dibenzoyl‐3,	 3'‐bis(4‐fluorophenyl)‐2,	 2'‐dithioxotetra	
hydro‐[5,	5'‐bipyrimidine]‐4,	4',	6,	6'(1H,	1'H,	5H,	5'H)‐tetraone	
(14):	Color:	White.	Yield:	70%.	M.p.:	124‐126	°C.	FT‐IR	(KBr,	,	
cm‐1):	3528	(OH),	1700,	1680,	1661	(C=O),	1385	(NCSN),	1255	
(C‐F),	1180	(C=S),	864	(Aryl	CH),	658	(C‐F).	1H	NMR	(400	MHz,	
CDCl3,	δ,	ppm):	2.589‐2.583	(m,	2H,	2CH),	7.01‐7.97	(m,	18H,	
Ar‐H),	9.84	(s,	1H,	OH),	11.32	(s,	1H,	OH).	13C	NMR	(100	MHz,	
CDCl3,	δ,	ppm):	166.31,	159.76,	158.16,	135.12,	135.10,	131.44,	
128.29,	128.23,	127.69,	126.60	122.39,	122.35	115.97,	115.82.	
115.17,	 115.03,	 77.84,	 45.85,	 40.32.	 MS	 (EI,	m/z	 (%)):	 684	
(M+2,	 3.53).	 UV/Vis	 (EtOH,	 λmax,	 nm,	 (ɛ)):	 282	 (0.2011).	 Anal.	
calcd.	 for	 C34H20F2N4O6S2:	 C,	 59.82;	 H,	 2.95;	 N,	 8.21;	 S,	 9.39.	
Found:	C,	59.77;	H,	2.90;	N,	7.99;	S,	9.28%.	
	
3.	Results	and	discussion		
	
3.1.	Chemistry	
	
Thiobarbituric	acids	have	activated	tautomers,	and	the	CH2	
at	position‐5	is	an	active	site	for	addition,	alkylation,	acylation	
and	 also	 condensation	 reactions	 [9,28,29].	 Thus,	 careful	
addition	of	4‐fluoroaniline	 to	 aryl	 isothiocyanates	 in	warmed	
THF	 produced	 compound	 1a‐c.	 Heterocyclization	 of	
compounds	1a‐c	by	reflux	with	malonic	acid	in	the	presence	of	
acetyl	 chloride‐acetic	 acid	mixture,	 yielded	 compounds	2a‐c.	
Addition	of	compounds	2a	to	cyclohexyl	isocyanate	in	warmed	
ethanol‐piperidine	furnished	compound	3	(Scheme	1).	Forma‐
tion	of	compound	3	took	place	by	a	nucleophilic	attack	of	CH2	
at	position‐5	of	compound	2a	with	a	more	electrophilic	carbon	
of	isocyanate.		
Structures	 of	 compounds	 1‐3	 were	 characterized	 from	
correlated	 elemental	 analysis	 and	 spectral	 data.	 The	 IR	
spectrum	of	compound	1a	 recorded	absorption	band	at	3180	
cm‐1	 attributed	 to	 presence	 of	 NH	 functional	 groups,	 which	
lacks	 in	 compound	 2a.	 Compounds	 2a‐b	 and	 3	 showed	 an	
absorption	bands	at	1680,	1668	and	at	2856,	1488	cm‐1	due	to	
the	presence	of	both	two	carbons	and	active	methylene.	Only,	
the	 spectrum	 of	 compound	3	 showed	 the	 third	 C=O	 and	 one	
NH	 functional	 group	 at	 1668	 and	 3180	 cm‐1.	 The	 1H	 NMR	
spectrum	of	 compound	2a	display	doublets	 at	δ	2.59‐2.58	 (s,	
2H,	CH2)	ppm	due	to	active	ethylene	at	5‐positions.	13C	NMR	of	
both	compound		2a	showed	a	resonated	signal	at	166.32	and	
158.17	ppm	for	C=O	and	C=S	carbons	with	resonated	=CH	at	δ	
40.43	ppm.	Compound	2a	exhibited	m/z	at	314	as	base	peak.	
UV	spectra	of	compound	3	are	more	than	compound	2	at	λmax	
(275	 and	 258	 nm)	 attributed	 to	 heteroconjugation	 systems	
formed.	It	is	interest	that,	compounds	2	and	3	showed	a	violet	
color	 with	 FeCl3	 solution	 which	 confirm	 that	 these	 systems	
exist	 as	 enolic	 form	 rather	 than	 ketonic	 formula.	 Reflux	
compound	3	with	glacial	acetic	acid	in	a	fused	sodium	acetate	
yielded	compound	4.	
Polyfunctional	pyrimidopyrimidines	use	as	multi‐targeted	
small	 molecule	 inhibitors	 and	 resistance	 modifying	 agents	
[30,31].	Similary,	cycloaddition	of	substituted	thiourea	1	with	
compound	3	in	methanolic	NaOH	produced	compounds	5	and	
6	 (Scheme	 1).	 Structures	 of	 compounds	 4‐6	 deduced	 from	
their	 correct	 elemental	 analysis	 and	 spectral	 measurements.	
IR	spectra	of	compound	5	and	6	showed		at	3150‐3123	cm‐1	
attributed	to	exo	‐NH‐	while	that	lacks	in	compound	4.	1H	NMR	
spectra	of	compound		6	recorded	signal	at	δ	11.55		ppm	for	NH	
protons.	13C	NMR	spectra	of	compounds	6	showed	δ	at	207.02	
and	157.10	ppm	for	C=S,	and	C=O	appeared	 for	compound	4.	
UV	absorption	spectrum	of	compound	6	exhibited	λmax	at	287	
nm	 which	 higher	 than	 compound	 3,	 which	 is	 due	 to	 more	
conjugation	system.	Compound	4	showed	a	molecular	ion	and	
a	 base	 peak	 at	 m/z	 422.	 Addition	 sulfa	 drugs	 as	 primary	
aromatic	 amines	 to	 benzoyl	 isothiocyanates	 in	 warm	 THF,	
produced	 compound	 7a‐c.	 Heterocyclization	 of	 compound	 7	
with	malonic	acid	in	warm	acetyl	chloride‐acetic	acid	produce	
compounds	 8a‐c.	 Which	 contain	 active	 CH2	 at	 position‐5.	
Treatment	of	compounds	8a,	b	with	4‐fluorobenzoyl	chloride	
in	 warm	DMF	 yielded	 compound	9.	 Ring	 closure	 reaction	 of	
compound	9	with	4‐chlorophenyl	hydrazine	in	reflux	absolute	
ethanol	afforded	compound	10a,	b	(Scheme	2).	
The	 former	 structure	 of	 compounds	 7‐10	 have	 been	
established	 from	 their	 corrected	 elemental	 analysis	 and	
spectral	data.	IR	spectra	showed	an	absorption	band	at	3500‐
3150	and	1580	cm‐1	for	(HO‐C=N	⇄	CO‐NH)	for	compound	7a‐
c.	 Also,	 compound	 9	 recorded	 a	 multi‐absorption	 bands	 at	
1680‐1660	cm‐1	attributed	to	four	C=O	functional	groups.	Only	
the	 compound	10b	 recorded	 an	 absorption	 band	 for	 C=N	 at	
1520	 cm‐1.	 All	 the	 IR	 spectra	 of	 compounds	7‐10	 showed	 an	
absorption	 band	 at	 	 for	 the	 acidic	 ‐NHSO2‐	 group.	 1H	 NMR	
spectra	of	compound	8a	recorded	a	resonated	signal	at	δ	2.60‐
2.21	 ppm	 for	 active	 CH2	 at	 position‐5.	 In	 addition	 13C	 NMR	
spectrum	 of	 compound	 8a	 showed	 a	 resonated	 signal	 at	 δ	
179.26,	 173.06	 and	 169.22	 ppm	 attributed	 to	 C=S	 and	 C=O	
carbons	with	 δ	 40.42‐39.47	ppm	 for	 CH2.	M+/S	 of	 compound	
8a	 recorded	 a	 base	 peak	 at	 m/z	 485.94.	 UV	 absorption	
spectrum	 of	 compound	10a	 exhibited	 λmax	 at	 315	 nm	 higher	
than	compounds	9,	8	and	7	(λ	at	294,	280	and	238	nm.	Mass	of	
compound	10b	 showed	 a	molecular	 ion	of	M‐24	with	 a	 base	
peak	 at	 722	m/z.	 Compound	 7	 showed	 a	 violet	 color	 when	
treated	 with	 FeCl3	 solution,	 which	 confirm	 that	 enolic	
structure	than	ketonic	formula	(enolization	preferred	towards	
aryl	groups).		
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Table	1.	Anti‐HIV	activity	data	of	the	thiobarbituric	acids	*.	
Compound	 IC50	(µM)	 EC50	(µM)	 CC50	(µM)	 SI	 Present	of	protection	 Present	of	infected	
2	 9.3±1.5	 48±1.7	 87.0±3.8 1.81 4.90 7.15	
8a	 4.5±0.2	 31±1.1	 60.0±5.5 19.35 7.95 9.88	
8b	 4.6±0.8	 2.3±0.5	 48.8±81 21.21 7.55 10.30	
8c	 3.1±0.5	 6.6±0.8	 41.01±40 6.21 12.15 13.55	
9a	 3.2±0.6	 24.08	2.8	 75.0±1.0	 3.12	 10.70	 11.51	
12	 7.7±0.1	 6.8±0.8	 36±2.6 5.29 5.88 7.90	
14	 2.7±0.1	 13.8±1.8	 28.5±1.3 2.06 16.01 15.11	
*	IC50:	The	half	maximal	 inhibitory	concentration	 is	a	measure	of	 the	effectiveness	of	a	compound	in	 inhibiting	biological	or	biochemical	function;	EC50:	The	
term	half	maximal	effective	concentration	refers	to	the	concentration	of	a	drug,	an	antibody	or	toxicant	which	induces	a	response	halfway	between	the	baseline	
and	maximum	after	a	specified	exposure	time;	CC50:	Cytotoxicity	concentration;	SI:	Selectivity	Index	CC50/EC50.	
		
	
Similarly,	 the	 addition	 of	 4‐fluoroaniline	 to	 benzoyl	
isothiocyanate	 in	 warm	 THF	 produce	 compound	 11.	
Heterocyclization	 of	 compound	11	 by	 refluxing	with	malonic	
acid	 in	 acetyl	 chloride‐acetic	 acid	 [32]	 yielded	 compound	12	
(Scheme	 3).	 It	 is	 interest	 that	 a	 simple	 alkylation	 of	 α‐active	
proton	 of	 compound	 12	 via	 nucleophilic	 attack	 to	 labile	
chloride	atom	containing	α‐keto‐alkylating	agents	[33,34].		
Alkylation	 of	 compound	 12	 by	 using	 dimethyl	 2‐chloro	
malonate	 in	 boiling	 dry	 toluene	 in	 the	 presence	 of	 drops	
triethylamine,	 compound	 13	 isolated.	 Full	 hetero‐cyclization	
of	compound	13	by	reaction	with	compound	11	in	reflux	THF,	
afforded	the	bis‐compound	14	(Scheme	3).	Former	structures	
of	 compound	 11‐14	 have	 been	 deduced	 from	 the	 corrected	
elemental	 analysis	 and	 spectral	 data.	 IR	 spectrum	 of	
compound	11	recorded	the	absorption	band	at	3230‐3150	cm‐
1	due	to	CONH	⇄	HO‐C=N,	 in	addition	at	1385	cm‐1	for	NCSN.	
On	 the	 other	 hand	 IR	 spectra	 of	 compounds	 12‐14	 showed	
absorption	 bands	 at	 	 1680,	 1660	 cm‐1	 attributed	 to	 1,3‐
dicarbonyl	 groups	 with	 characteristic	 bands	 at	 	 1211	 and	
1180	 	 cm‐1	 for	 C=S	 groups	 and	 1255	 cm‐1	 for	 C‐F.	 13C	 NMR	
spectrum	 of	 compound	 14	 showed	 a	 resonated	 signals	 at	
166.31	and	159.76	ppm	attributed	to	C=S	and	C=O	carbons,	in	
addition	at	δ	131.41‐122.35	and	45.85,	40.32	ppm	for	aromatic	
and	 aliphatic	 carbons.	 UV	 absorption	 spectra	 of	 compounds	
11‐14	 give	 us	 indication	 about	 the	 ring	 closure	 reactions	 of	
compound	11	to	13	and	14.	Compound	11	showed	λmax	at	265	
nm,	compound	12	at	288	and	compound	14	at	282	nm.	These	
data	 confirm	 that	 formation	 of	 heterocyclic	 systems	 from	
compounds	 11	 to	 12.	 Mass	 of	 compound	 14	 exhibited	 a	
molecular	 ion	and	 the	base	peaks	at	m/z	684	(M+2)	and	685	
(M+3).	
	
3.2.	Pharmacological	Evaluation	
	
Recently,	thiobarbituric	acid	derivatives	proved	to	be	virus	
inhibitors,	 especially	 hepatitis’s	 C	 virus	 (HCV)	 NS5B	
polymerase.	Besides,	they	suppressed	the	synthesis	of	RNA	by	
recombinant	 HCV	 NS5B	 polymerase	 dependent	 manner	 [35‐
39].	The	prominent	role	of	 fluorine	substituent	on	bioactivity	
is	 due	 to	 the	 effect	 C‐H	 acidity	 which	 depends	 on	 several	
factors,	 including	 the	site	of	 fluorination	and	 the	geometry	of	
the	 conjugate	 carbon	 ion.	 Based	 on	 these	 observations,	 The	
present	work	depends	on	the	synthesis	of	fluorine	substituted	
thiobarbituric	 acid	 derivatives	 and	 their	 related	 heterocyclic	
systems	and	their	evaluation	as	potential	inhibitors,	especially	
HIV‐1	and	 inhibition	of	cyclin‐dependent	kinase	2	(CDK2)	for	
tumor	cell.	
	
3.2.1.	Anti‐HIV‐1	Testing	
	
All	the	new	synthesized	compounds	evaluated	for	their	 in	
vitro	anti‐	HIV	activities	were	performed	on	T‐4	Lymphocytes	
uninfected	or	infected	with	HIV‐1	using	DMSO	as	solvent.	The	
assay	 basically	 involves	 the	 killing	 T‐4	 Lymphocytes	 by	 HIV.	
Compounds	that	degenerate	or	are	rapidly	metabolized	in	the	
culture	conditions	may	not	show	activity	in	this	screening.	The	
viability	 of	 the	 cells	 was	 determined	 spectrophotometrically	
using	the	tetrazolium	assay	procedure.	The	concentration	was	
tested	range	1×10‐4	to	1×10‐8	M	and	determined	GI50,	TGI	and	
LC50	values.	
The	arrangements	of	 atoms	across	 the	 skeleton,	 concepts	
of	 steric	 relations	 and	 molecular	 bulk	 branched	 ness	 and	
relationships	 among	 various	 non‐branched	 parts	 of	 the	
molecule	 are	 considered	 in	 these	 methods.	 Thus,	 we	 report	
here	 the	 correlation	 of	 cytotoxicity	 and	 anti‐HIV	 activity	 of	
fluorinated	thiobarbituric	acid	derivatives	in	view	to	provide	a	
better	 rational	 approach	 for	 the	 design	 of	 potent	 drugs.	 The	
electronic	 parameter	 (equalized	 electronegativity)	 hydro‐
phobic	parameter	and	steric	parameter	of	 the	 tested	systems	
synthesized	 give	 us	 a	 good	 indication	 about	 the	 role	 of	
electronic	 nature,	 hydrophobicity,	 and	 molecular	 size	 of	 the	
fluorinated	 thiobarbituric	 acid	 derivatives	 molecules	 on	 the	
activity.	 HIV‐1	 envelope	 glycoprotein	 (Env)	 transmembrane	
submit	 glycoprotein	 41	 (gp41)	 plays	 a	 crucial	 role	 in	
mediating	 virus,	 fusion	 and	 entry.	 When	 the	 human	
immunodeficiency	 virus	 (HIV)	 fuses	 to	 the	 host	 cell,	 the	 N‐
terminal	heptads	repeat	(NHR)	and	C‐terminal	heptads	repeat	
(CHR)	of	gp41	interact	to	form	a	six‐helix	bundles	(6‐HB)	core	
structure,	 bringing	 the	 viral	 and	 host	 cell	 membranes	 into	
sufficient	 proximity	 to	 allow	 fusion.	 The	 fluorinated	
thiobarbituric	acid	derivatives	synthesized	were	evaluated	as	
anti‐HIV	 and	 the	 results	 were	 obtained	 reported	 in	 Table	 1	
[40].	From	the	data	obtained	it	can	be	concluded	that	the	order	
of	activity	of	these	targets	is	14	>	8c	>	9a	>	8a	>	8b	>	12	>	2.	
The	most	activity	compounds	14,	8c,	9a	and	8a	which	are	due	
to	 the	 presence	 of	 fluorine	 substituted	 thiobarbituric	 acids.	
These	active	compounds	exhibited	significant	potency	against	
gp41	6‐HB	 formation	with	 IC50	 values	 of	 4.5	 and	 4.6	 µM	 and	
against	HIV‐1	replication	in	the	MT‐2	cells	with	EC50	values	of	
3.1	 and	 3.2	 µM,	 respectively.	 Thus,	 providing	 a	 new	 starting	
point	 to	 develop	 highly	 potent	 small	 molecule	 HIV	 fusion	
inhibitors	 targeting	gp41.	On	 the	other	hand,	 compounds	14,	
8c,	9a	and	8a	 recorded	a	higher	percent	of	protection	(Table	
1).	
	
3.2.2.	Inhibition	of	cyclin‐dependent	kinase2	(CDK2)	for	
cell‐tumor	division	
	
Various	 thiobarbituric	 acid	 derivatives	 exhibited	
anticancer	activities	[40,41].	A	recent	control	on	the	cell	tumor	
division	 depends	 on	 the	 use	 of	 polyfunctional	 heterocyclic	
nitrogen	 systems	 for	 inhibition	 of	 cyclin‐dependent	 kinase	 2	
(CDK2)	 as	 tyrosine	 kinase	 inhibitors	 [42].	 Thus,	 the	 present	
work	 aimed	 to	 prepare	 of	 new	 fluorine	 substituted	
thiobarbituric	 acid	 derivatives	 and	 their	 heterobicyclic	
nitrogen	 systems	 as	 a	 novel	 scaffold	 for	 the	 development	 of	
antiproliferative	 agents	 with	 possible	 pharmacological	
applications	 in	 oncology.	 The	 synthesized	 compounds	 were	
evaluated	 for	 their	 ability	 to	 inhibit	 acidity	 of	 CDK2	 in	 a	
biochemical	 assay	 [43]	 with	 IC50	 values	 comparable	 to	
olomoucine	 as	 standard	 according	 to	 the	 reported	 methods.	
The	 obtained	 data	 were	 reported	 in	 Table	 2.	 In	 view	 of	 the	
results	 obtained,	 the	most	 active	 compounds	 bear	 a	 fluorine	
atom	 followed	 by	 a	 sulfa‐drug	 moiety.	 In	 addition,	 we	
observed	 that	 a	 4‐fluorophenyl	 side	 chain	 at	 position	 1	 or	 3	
significantly	decreases	CDK2	inhibitory	acidity.	The	activity	of	
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the	 tested	 targets	 as	 12	 >	 14	 >	 2	 >	 9a	 >	 8a	 >	 8b	 >	 8c	 in	
comparing	with	olomoucine	as	standard.	
	
Table	2.	Results	CDK2	inhibition	tests	(IC50	in	µmol/dm)	*.	
Compound	 IC50	CDK2±SD	(µM)
2	 11.0±4.5	
8a	 15.1±5.3	
8b	 17.4±3.8	
8c	 >20	
9a	 14.1±1.8	
12	 4.5±2.8	
14	 5.2±1.73	
Olomoucine	 5.0±1.0	
*	SD:	Standard	deviation,	Olomoucine	value	is	included	as	a	control.	
	
4.	Conclusion	
	
Simple	routs	were	explored	to	synthesize	new	fluorinated	
fused	 heterobicyclic	 systems	 containing	 a	 thiobarbituric	 acid	
moiety	starting	with	fluorinated	N,Nʹ‐diarylthiobarbituric	acid,	
2.	Some	of	new	synthesized	systems	recorded	good	anti	HIV‐1	
and	 cyclin	 dependent	 kinase	 2.	 We	 hope	 that	 this	 approach	
may	 be	 a	 value	 to	 others	 seeking	 novel	 synthetic	 fragments	
with	unique	properties	for	medicinal	chemistry.		
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